Physicians forced to deal with ‘doctor shopping’ patients thanks to new regulations

State-by-state, physicians will find differing standards on when they’re required to check prescription drug monitoring databases before prescribing opioids, even as their professional organizations continue to fight mandatory requirements.

According to the Washington Post, 18 states now require opioid prescribers to check these databases to ensure patients aren’t getting potentially addictive drugs from other doctors. 13 more states have mandatory checks in limited circumstances. Researchers say making physicians check the databases has been proven to cut down on “doctor shopping” and change prescribing habits.

The American College of Physicians and American Medical Association (AMA), however, continue to support only voluntary checks, arguing it places another burden on already overwhelmed physicians.

“We have taken doctors and turned them into clerical staff and typists,” said Steven Stack, MD, past president of the AMA. “We are locked down at a computer, playing the equivalent of a very boring video game on very bad technology.”

For more on the battle between lawmakers and physicians in addressing opioid prescriptions and addiction, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.